EcoDrugPlus

Snake Venom 5'-Nucleotidase

Ensembl ID : ENSLCAG00010021363
Gene Symbol: LOC108874909
4 Cross references
180 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSLCAG00010025085
Gene Symbol: SCN5LAB
1 Cross references
262 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSLCAG00010005031
Gene Symbol: SCN12AA
1 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSLCAG00010019195
Gene Symbol: SCN4A
2 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSLCAG00010012545
Gene Symbol: SCN8A
2 Cross references
215 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3

Ensembl ID : ENSLCAG00010023587
Gene Symbol: LOC108883733
4 Cross references
236 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3

Ensembl ID : ENSLCAG00010002669
Gene Symbol: LOC108902943
3 Cross references
232 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSLCAG00010017446
Gene Symbol: SLC10A2
2 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSLCAG00010016127
Gene Symbol: LOC108884808
4 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6, Like

Ensembl ID : ENSLCAG00010008868
Gene Symbol: SLC22A6L
4 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSLCAG00010011360
Gene Symbol: SLC29A1
4 Cross references
210 Possible Orthologues:

Solute Carrier Family 29 Member 1a

Ensembl ID : ENSLCAG00010001576
Gene Symbol: SLC29A1A
1 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).